Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 11.13
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of VERV is 14 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Data is available to registered users only
